Biohaven’s drug for genetic neurological disease fails late-stage study

(Reuters) – Biohaven Pharmaceutical said on Monday a late-stage trial of its drug against a genetic neurological disease failed to meet the primary goal of the study.

(Reporting by Leroy Leo in Bengaluru; Editing by Aditya Soni)